ID26334A - Morfolinol yang aktif secara farmasi - Google Patents

Morfolinol yang aktif secara farmasi

Info

Publication number
ID26334A
ID26334A IDW20001597A ID20001597A ID26334A ID 26334 A ID26334 A ID 26334A ID W20001597 A IDW20001597 A ID W20001597A ID 20001597 A ID20001597 A ID 20001597A ID 26334 A ID26334 A ID 26334A
Authority
ID
Indonesia
Prior art keywords
morpholinol
activate
pharmaceutical
pharmaceutical activate
activate morpholinol
Prior art date
Application number
IDW20001597A
Other languages
English (en)
Indonesian (id)
Inventor
Phillip Frederick Morgan
David Lee Musso
John Joseph Partridge
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9801230.5A external-priority patent/GB9801230D0/en
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of ID26334A publication Critical patent/ID26334A/id

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
IDW20001597A 1998-01-21 1999-01-20 Morfolinol yang aktif secara farmasi ID26334A (id)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9801230.5A GB9801230D0 (en) 1998-01-21 1998-01-21 Pharmaceutically active morpholinol
US7218098P 1998-01-22 1998-01-22

Publications (1)

Publication Number Publication Date
ID26334A true ID26334A (id) 2000-12-14

Family

ID=26312986

Family Applications (1)

Application Number Title Priority Date Filing Date
IDW20001597A ID26334A (id) 1998-01-21 1999-01-20 Morfolinol yang aktif secara farmasi

Country Status (30)

Country Link
US (2) US6274579B1 (de)
EP (2) EP1047428B1 (de)
JP (1) JP2002501025A (de)
KR (1) KR100568063B1 (de)
CN (2) CN1203858C (de)
AP (1) AP1229A (de)
AT (1) ATE365042T1 (de)
AU (1) AU755536B2 (de)
BR (1) BR9907203A (de)
CA (1) CA2318268A1 (de)
CY (1) CY1106828T1 (de)
DE (1) DE69936335T2 (de)
DK (1) DK1047428T3 (de)
EA (1) EA002410B1 (de)
EE (1) EE04452B1 (de)
ES (1) ES2288012T3 (de)
HR (2) HRP20051024A2 (de)
HU (1) HUP0100900A3 (de)
ID (1) ID26334A (de)
IL (2) IL161942A0 (de)
IS (1) IS2494B (de)
NO (2) NO326878B1 (de)
NZ (3) NZ520349A (de)
PL (1) PL193622B1 (de)
PT (1) PT1047428E (de)
SG (1) SG115489A1 (de)
SK (1) SK10912000A3 (de)
TR (1) TR200002126T2 (de)
WO (1) WO1999037305A1 (de)
YU (1) YU67102A (de)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7098206B2 (en) * 1998-01-21 2006-08-29 Smithkline Beecham Corporation Pharmaceutically active morpholinol
US6998400B2 (en) 1998-01-22 2006-02-14 Smithkline Beecham Corporation Pharmaceutically active morpholinol
AU2483599A (en) 1998-01-29 1999-08-16 Sepracor, Inc. Pharmaceutical uses of optically pure (-)-bupropion
AU2349999A (en) * 1998-01-29 1999-08-16 Sepracor, Inc. Pharmacological uses of pure (+) -bupropion
US6855820B2 (en) 1999-01-20 2005-02-15 Smithkline Beecham Corporation Pharmaceutically active morpholinol
US6734213B2 (en) 1999-01-20 2004-05-11 Smithkline Beecham Corporation Pharmaceutically active morpholinol
US6337328B1 (en) * 1999-03-01 2002-01-08 Sepracor, Inc. Bupropion metabolites and methods of use
US6342496B1 (en) 1999-03-01 2002-01-29 Sepracor Inc. Bupropion metabolites and methods of use
EP1220673A2 (de) * 1999-10-13 2002-07-10 Glaxo Group Limited Morpholinol-verbindungen zur behandlung von fettleibigkeit
GB0003232D0 (en) * 2000-02-11 2000-04-05 Smithkline Beecham Plc Novel composition
US7145649B2 (en) * 2000-12-21 2006-12-05 Brasscorp Limited Method of producing an ultra-violet or near ultra-violet light source for non-destructive inspection or testing
US6979104B2 (en) 2001-12-31 2005-12-27 R.J. Doran & Co. LTD LED inspection lamp
EP3173082A1 (de) 2002-05-17 2017-05-31 Duke University Verfahren zur behandlung von adipositas
US20050215552A1 (en) * 2002-05-17 2005-09-29 Gadde Kishore M Method for treating obesity
GB0219687D0 (en) * 2002-08-23 2002-10-02 Lilly Co Eli Benzyl morpholine derivatives
WO2004017977A2 (en) * 2002-08-23 2004-03-04 Eli Lilly And Company 2- (phenoxymethyl)- and 2- (phenylthiomethyl)-morpholine derivatives for use as selective norepinephrine reuptake inhibitors
HUE034290T2 (en) 2003-04-29 2018-02-28 Orexigen Therapeutics Inc Preparations containing opioid antagonist and bupropion to affect weight loss
US20070093486A1 (en) * 2003-10-27 2007-04-26 Smith Kline Beecham Corporation ,Corporation Enzyme-catalyzed dynamic kinetic resolution process for preparing (+)-(2s,3s)-2-(3-chlorophenyl)-3,5,5-trimethyl-2-morpholinoland salts and solvates thereof
GB0325055D0 (en) * 2003-10-27 2003-12-03 Smithkline Beecham Corp New process
GB0326148D0 (en) * 2003-11-10 2003-12-17 Lilly Co Eli Morpholine derivatives
GB0327195D0 (en) * 2003-11-21 2003-12-24 Smithkline Beecham Corp Novel use
GB0327619D0 (en) * 2003-11-27 2003-12-31 Smithkline Beecham Corp New use
US7429580B2 (en) * 2004-01-13 2008-09-30 Orexigen Therapeutics, Inc. Compositions of an anticonvulsant and an antipsychotic drug and methods of using the same for affecting weight loss
US7713959B2 (en) * 2004-01-13 2010-05-11 Duke University Compositions of an anticonvulsant and mirtazapine to prevent weight gain
RU2006139930A (ru) * 2004-05-03 2008-06-10 Дюк Юниверсити (Сша/Сша) (Us) Составы для содействия снижению веса
FI117283B (fi) 2005-02-04 2006-08-31 Kone Corp Hissijärjestelmä
CA2630624C (en) 2005-11-22 2013-08-06 Orexigen Therapeutics, Inc. Compositions and methods for increasing insulin sensitivity
CA2635261A1 (en) * 2006-01-03 2007-07-12 Algebra, Inc. Therapeutic amine-arylsulfonamide conjugate compounds
US8916195B2 (en) 2006-06-05 2014-12-23 Orexigen Therapeutics, Inc. Sustained release formulation of naltrexone
KR20170077291A (ko) 2006-11-09 2017-07-05 오렉시젠 세러퓨틱스 인크. 단위 용량 팩키지
TWI609702B (zh) 2006-11-09 2018-01-01 歐瑞根治療有限公司 層狀醫藥調配物
US20090075994A1 (en) * 2007-09-14 2009-03-19 Protia, Llc Deuterium-enriched radafaxine
JP2011521973A (ja) 2008-05-30 2011-07-28 オレキシジェン・セラピューティクス・インコーポレーテッド 内臓脂肪の状態を処置するための方法
EP2419400A1 (de) 2009-04-15 2012-02-22 Research Triangle Institute Monoaminwiederaufnahmehemmer
ES2762113T3 (es) 2010-01-11 2020-05-22 Nalpropion Pharmaceuticals Inc Métodos de proporcionar terapia de pérdida de peso en pacientes con depresión mayor
JP2013526583A (ja) 2010-05-21 2013-06-24 リサーチ・トライアングル・インスティチュート フェニルモルホリンおよびその類似体
CA2800219C (en) 2010-05-21 2019-03-12 Research Triangle Institute 1 - phenylmorpholine derivatives as hydroxybupropion analogues for treating drug dependence
US9510405B2 (en) 2011-06-30 2016-11-29 Schneider Electric Industries Sas Dual power SMPS for a modular lighting system
CN102670617B (zh) * 2012-04-13 2013-03-20 湖南大学 布洛芬2-（2-芳基吗啉-4-基）乙酯作为制备抗抑郁药物的应用
LT3730132T (lt) 2012-06-06 2022-08-25 Nalpropion Pharmaceuticals Llc Kompozicija, skirta panaudoti pacientų su didele širdies ir kraujagyslių ligų rizika antsvorio ir nutukimo gydymo būde
CN105949142B (zh) * 2016-05-21 2018-03-27 南华大学 具有抗抑郁活性的单一手性化合物及其制备方法和应用
RU2763728C1 (ru) * 2021-06-17 2021-12-30 Федеральное государственное автономное образовательное учреждение высшего образования "Пермский государственный национальный исследовательский университет" (ПГНИУ) Применение 3-(2-(4-нитрофенил)-2-оксоэтилиден)морфолин-2-она в качестве средства, обладающего противомикробной активностью

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US170430A (en) * 1875-11-30 Improvement in furnaces for heating steel in tempering
GB8417170D0 (en) * 1984-07-05 1984-08-08 Wellcome Found Heterocyclic pharmaceutical compounds
GB9108629D0 (en) 1991-04-23 1991-06-12 Wellcome Found Heterocyclic pharmaceutical compounds,preparation and use
US6337328B1 (en) 1999-03-01 2002-01-08 Sepracor, Inc. Bupropion metabolites and methods of use

Also Published As

Publication number Publication date
YU67102A (sh) 2004-12-31
JP2002501025A (ja) 2002-01-15
HUP0100900A3 (en) 2002-08-28
AP1229A (en) 2003-12-04
IS2494B (is) 2009-02-15
HRP20000494A2 (en) 2000-12-31
EE04452B1 (et) 2005-04-15
WO1999037305A1 (en) 1999-07-29
AU755536B2 (en) 2002-12-12
CN1255389C (zh) 2006-05-10
DK1047428T3 (da) 2007-10-08
BR9907203A (pt) 2000-10-17
CN1294513A (zh) 2001-05-09
HUP0100900A2 (hu) 2002-05-29
TR200002126T2 (tr) 2000-12-21
EA002410B1 (ru) 2002-04-25
AP2000001869A0 (en) 2000-09-30
SK10912000A3 (sk) 2001-04-09
EP1829544A1 (de) 2007-09-05
KR20010034285A (ko) 2001-04-25
IL161942A0 (en) 2005-11-20
US6274579B1 (en) 2001-08-14
CA2318268A1 (en) 1999-07-29
ATE365042T1 (de) 2007-07-15
US6391875B2 (en) 2002-05-21
EP1047428A1 (de) 2000-11-02
EA200000691A1 (ru) 2001-04-23
SG115489A1 (en) 2005-10-28
AU2328099A (en) 1999-08-09
CN1203858C (zh) 2005-06-01
US20020019396A1 (en) 2002-02-14
CN1528753A (zh) 2004-09-15
IL137346A0 (en) 2001-07-24
HRP20051024A2 (hr) 2006-04-30
NZ529316A (en) 2004-05-28
EP1047428A4 (de) 2001-12-19
ES2288012T3 (es) 2007-12-16
HRP20000494B1 (en) 2009-02-28
NZ520349A (en) 2004-02-27
NO20083529L (no) 2000-09-19
EP1047428B1 (de) 2007-06-20
KR100568063B1 (ko) 2006-04-07
NZ505809A (en) 2002-09-27
DE69936335T2 (de) 2008-02-28
DE69936335D1 (de) 2007-08-02
PT1047428E (pt) 2007-09-07
CY1106828T1 (el) 2012-05-23
NO20003721D0 (no) 2000-07-20
NO20003721L (no) 2000-09-19
PL342012A1 (en) 2001-05-07
NO326878B1 (no) 2009-03-09
PL193622B1 (pl) 2007-02-28
EE200000438A (et) 2001-12-17
IS5568A (is) 2000-07-20

Similar Documents

Publication Publication Date Title
ID26334A (id) Morfolinol yang aktif secara farmasi
ID28110A (id) Surfaktan alkilbenzenasulfonat yang disempurnakan
ID27841A (id) Turunan-turunan biaril terapeutik
IS5425A (is) Læknislyf
NO992339L (no) Farmasöytiske formuleringer
DE69924365D1 (de) Massagegerät
ID26330A (id) Polipeptida-polipeptida yang bergantung vitamin k yang dimodifikasi
ID27415A (id) Komposisi farmaseutik
ID22939A (id) Formulasi-formulasi farmasi yang mengandung vorikonozal
NO992692L (no) Nefadozon doseringsform
ID29262A (id) Komposisi farmasi
DE69921571D1 (de) Massagegerät
DK1466615T3 (da) Farmaceutisk præparat
ID23735A (id) Tablet trovafloksasin mesilat
DE69908262D1 (de) Sprühbehälter
ID27201A (id) Komposisi farmasi
ID30032A (id) Formulasi farmasi
EP1061784A4 (de) Radioelektronische einheit
NO994619L (no) Farmasöytiske blandinger
EP1074250A4 (de) Zuckerbeschichtete tabletten
NO20003141D0 (no) Farmasøytiske blandinger
FR2782671B3 (fr) Livre
DK1051156T3 (da) Farmaceutiske præparater
DE59904743D1 (de) Exzenteranordnung
ID27593A (id) Tetrahidronaftilidinil-karboksamida yang mempunyai aktivitas anti-konvulsan